Xilio Therapeutics

Xilio Therapeutics, formerly known as Akrevia Therapeutics, is a biotech company developing potent, tumor-selective immuno-oncology (IO) therapies for patients with cancer.

Xilio is advancing next-generation cancer immunotherapies designed to improve patient outcomes by unleashing the power of the immune system selectively at the site of the tumor.

Xilio was founded in 2016 and is headquartered in Waltham, Massachusetts.

 

Xilio's tumor-selective immunotherapies are based on its proprietary technology, which maximizes the potency of proven immuno-oncology therapies and restricts their activity to the tumor to minimize peripheral side effects.

 

Xilio is applying its technology to build a broad pipeline of engineered antibodies, cytokines and chemokines as potential new options for people living with cancer. The broad applicability of these therapies across cancer types means that all patients could benefit from these potentially curative medicines.

 

Xilio is backed by F-Prime Capital, Takeda Ventures, SV Health Investors, MRL Ventures Fund, RiverVest Venture Partners, Bay City Capital and others. The company raised $100.5M in a Series B round on Mar 02, 2020. This brings Xilio's total funding to $130.5M to date.

 

 

  • Year founded: 2016
  • Funding Info: $130.5M over 2 Rounds (Latest Funding Type: Series B)
  • Yearly Revenue: NA
  • Employee Size: 11-50
  • Business Valuation: NA
  • City/Town: Boston
  • State: Massachusetts
  • Country: United States
Related businesses